Radiomics-based ensemble model predicts postoperative recurrence of gastric cancer.
[BACKGROUND] Early postoperative recurrence in locally advanced gastric cancer (LAGC) severely compromises patient outcomes, yet current predictive models are inadequate due to limited generalizabilit
- 표본수 (n) 569
- p-value P < 0.001
APA
Ding P, Chen S, et al. (2025). Radiomics-based ensemble model predicts postoperative recurrence of gastric cancer.. BMC medicine, 23(1), 656. https://doi.org/10.1186/s12916-025-04393-4
MLA
Ding P, et al.. "Radiomics-based ensemble model predicts postoperative recurrence of gastric cancer.." BMC medicine, vol. 23, no. 1, 2025, pp. 656.
PMID
41291636
Abstract
[BACKGROUND] Early postoperative recurrence in locally advanced gastric cancer (LAGC) severely compromises patient outcomes, yet current predictive models are inadequate due to limited generalizability and insufficient validation. This study aimed to establish and robustly validate a multimodal Radiomics-Clinical Integrated Risk Stratification Assessment (RSA) model to accurately predict early recurrence.
[METHODS] We retrospectively analyzed 2,516 LAGC patients from six hospitals across northern and southern China, divided into training, internal validation, and external validation cohorts. Radiomics features were extracted from portal venous-phase abdominal CT images using nnU-Net-based segmentation, followed by a hierarchical feature-selection framework integrating the mRMR algorithm and LASSO regression. A predictive RSA model combining clinical factors and radiomics features was developed. Model robustness was validated internally, externally, prospectively (clinical trial cohort, NCT01516944, n = 569), and further independently tested using a publicly available dataset from The Cancer Imaging Archive (TCIA, n = 41).
[RESULTS] The RSA model exhibited superior performance across all validation cohorts, achieving AUC values of 0.873 (training), 0.871-0.872 (internal validation), 0.870-0.873 (external validation), 0.857 (prospective validation), and 0.850 (TCIA validation). Decision curve analyses confirmed the RSA model provided significant clinical benefits beyond traditional models. Transcriptomic analyses revealed that low-risk patients exhibited enhanced immune infiltration and significant activation of immune-related pathways, including IL6/JAK/STAT3 and interferon signaling. Multivariate Cox regression demonstrated the RSA model independently predicted five-year overall survival across validation cohorts (HR range: 1.830-2.166, all P < 0.001), surpassing standard clinical staging.
[CONCLUSIONS] Our RSA model, integrating robust radiomics methodologies and critical clinical parameters, consistently demonstrated high accuracy and clinical applicability in diverse populations, significantly improving prediction of early postoperative recurrence in LAGC. This approach provides novel insights into tumor-immune microenvironment interactions, paving the way toward personalized postoperative management strategies.
[METHODS] We retrospectively analyzed 2,516 LAGC patients from six hospitals across northern and southern China, divided into training, internal validation, and external validation cohorts. Radiomics features were extracted from portal venous-phase abdominal CT images using nnU-Net-based segmentation, followed by a hierarchical feature-selection framework integrating the mRMR algorithm and LASSO regression. A predictive RSA model combining clinical factors and radiomics features was developed. Model robustness was validated internally, externally, prospectively (clinical trial cohort, NCT01516944, n = 569), and further independently tested using a publicly available dataset from The Cancer Imaging Archive (TCIA, n = 41).
[RESULTS] The RSA model exhibited superior performance across all validation cohorts, achieving AUC values of 0.873 (training), 0.871-0.872 (internal validation), 0.870-0.873 (external validation), 0.857 (prospective validation), and 0.850 (TCIA validation). Decision curve analyses confirmed the RSA model provided significant clinical benefits beyond traditional models. Transcriptomic analyses revealed that low-risk patients exhibited enhanced immune infiltration and significant activation of immune-related pathways, including IL6/JAK/STAT3 and interferon signaling. Multivariate Cox regression demonstrated the RSA model independently predicted five-year overall survival across validation cohorts (HR range: 1.830-2.166, all P < 0.001), surpassing standard clinical staging.
[CONCLUSIONS] Our RSA model, integrating robust radiomics methodologies and critical clinical parameters, consistently demonstrated high accuracy and clinical applicability in diverse populations, significantly improving prediction of early postoperative recurrence in LAGC. This approach provides novel insights into tumor-immune microenvironment interactions, paving the way toward personalized postoperative management strategies.
MeSH Terms
Aged; Female; Humans; Male; Middle Aged; China; Neoplasm Recurrence, Local; Radiomics; Retrospective Studies; Risk Assessment; Stomach Neoplasms; Tomography, X-Ray Computed; Clinical Trials as Topic
같은 제1저자의 인용 많은 논문 (5)
- LukS-PV targeting C5aR inhibits EMT in hepatocellular carcinoma via the BCL6/HDAC6/HSPD1 axis.
- A deep learning-based digital biopsy for predicting early recurrence in gastric cancer.
- Interpretable Multimodal Fusion Model Enhances Postoperative Recurrence Prediction in Gastric Cancer.
- Multimodal Artificial Intelligence-Based Virtual Biopsy for Diagnosing Abdominal Lavage Cytology-Positive Gastric Cancer.
- Non-invasive liquid biopsy based on transcriptomic profiling for early diagnosis of occult peritoneal metastases in locally advanced gastric cancer.